Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
409results about How to "Shrink tumor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
RNA containing composition for treatment of tumor diseases
ActiveUS20160331844A1Improve survivalEffectively treating tumor and/or cancer diseasesSsRNA viruses negative-senseOrganic active ingredientsDiseasePharmaceutical drug
Owner:CUREVAC SE
Detection of necrotic malignant tissue and associated therapy
InactiveUS6017514AGuaranteed monitoring effectShrink tumorPeptide/protein ingredientsRadioactive preparation carriersAbnormal tissue growthAntigen
Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor. Also disclosed are antibodies for use with the foregoing methods.
Owner:PEREGRINE PHARMA INC +1
Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
ActiveUS7964571B2Inhibiting growth and metastasisImprove survivalHeavy metal active ingredientsPeptide/protein ingredientsGene deliveryWhole body
Owner:CLSN LAB
Chimeric Newcastle disease viruses and uses thereof
ActiveUS8591881B2Prevents progression and worseningReduce severitySsRNA viruses negative-senseBiocideNewcastle disease virus NDVAntagonist
Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.
Owner:MT SINAI SCHOOL OF MEDICINE +1
Globo h and related Anti-cancer vaccines with novel glycolipid adjuvants
ActiveUS20100136042A1Shrink tumorInhibit tumor growthOrganic active ingredientsSugar derivativesDendritic cellAdjuvant
Owner:ACAD SINIC
Treatment Of Tumors Expressing Mutant EGF Receptors
InactiveUS20090311803A1Reduces and prevents signalingShrink tumorAntibody ingredientsImmunoglobulinsAntibodyEGF Receptors
The invention discloses methods for identifying antibodies that reduce or prevent signaling by intact epidermal growth factor receptor (EGFR), or mutant EGFRs, such as EGFRvIII.
Owner:WAY JEFFREY C +4
Use of Pegylated IL-10 to Treat Cancer
InactiveUS20080081031A1Improved modulator of tumor growthReducing and inhibiting growth of tumorPeptide/protein ingredientsDigestive systemAbnormal tissue growthOncology
Owner:SCHERING CORP
Methods of treating bladder cancer
InactiveUS20140056986A1Many symptomDelaying progressing of bladder cancerPowder deliveryPeptide/protein ingredientsNanoparticleSurgery
The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise a taxane and an albumin.
Owner:ABRAXIS BIOSCI LLC
Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
InactiveUS6855723B2Reduce probabilityAlleviating and abrogating abnormal conditionBiocideOrganic chemistryBiological bodyThreonine
The present invention is directed in part towards methods of modulating the function of serine / threonine protein kinases with azabenzimidazole-based compounds. The methods incorporate cells that express a serine / threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine / threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to azabenzimidazole compounds and pharmaceutical compositions comprising these compounds.
Owner:ZENTARIS GMBH
Carrier-antibody compositions and methods of making and using the same
ActiveUS9533058B2Shrink tumorSmall sizeOrganic active ingredientsHeavy metal active ingredientsMedicineCarrier protein
Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Method of optimizing radiosurgery and radiotherapy with metalloporphyrins
InactiveUS7110808B2Great flexibilityShrink tumor sizeOrganic active ingredientsTelevision system detailsMedical physicsDual delivery
An apparatus and method for subsequent optimization of radiosurgery and radiotherapy is provided. The invention includes administering a metalloporphyrin to the patient, and then creating a 3-dimensional mapping of tissue through use of PET or SPECT. Malignant and pre-malignant tissue has an affinity for the metalloporphyrin. During treatment, real-time images are also provided which are compared to the previous 3-dimensional mapping. Creation of the real-time images is also achieved through PET or SPECT wherein a metalloporphyrin is administered to the patient. Total administration of radiation is calculated by summing radiation from the metalloporphyrins and from the radiosurgery / radiotherapy. The amount of radiation delivered by the metalloporphyrins and by the radiosurgery / radiotherapy are adjustable based on a patient's response to the dual delivery.
Owner:ADAIR
Method for enhancing specific immunotherapies in cancer treatment
ActiveUS20140086932A1Enhance immune functionGood curative effectSnake antigen ingredientsPharmaceutical delivery mechanismCompound (substance)Targeted immunotherapy
Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.
Owner:PROVIDENCE HEALTH & SERVICES OREGON D B A EARLE A CHILES RES INST OF THE ROBERT W FRANZ CANCER RES CENT AT PROVIDENCE PORTLAND MEDICAL CENT +1
Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
InactiveUS6410052B1Potent therapeutic effectReduce adverse effect on normal ,BiocideHydroxy compound active ingredientsUnknown primaryDietary product
The invention described herein encompasses a methods and compositions of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, a group of polyphenols found in green tea, to a mammal in need of such therapy. Compositions of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). The unique compositions of the invention contain various combinations of the catechins, alone or in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses the varying modes of administration of the therapeutic compounds, including a sustained release formulation which may be used as a therapeutic compound for the treatment of cancer or as a dietary supplement for the prevention of cancer.
Owner:PURDUE RES FOUND INC +1
Methods of treating cancer
ActiveUS20120070502A1High elongationLow toxicityPowder deliveryOrganic active ingredientsCarboplatinPlatinum
The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
Owner:ABRAXIS BIOSCI LLC
Compositions and methods for treatment and detection of cancers
ActiveUS20150344551A1Shrink tumorEliminate the problemImmunoglobulins against animals/humansAntibody ingredientsCancer cellAntigen Binding Fragment
Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and / or prostate cancer.
Owner:ACAD SINIC
Antibody/drug conjugates and methods of use
ActiveUS20140127241A1Reducing and inhibiting proliferationReducing and inhibiting and growthAntibacterial agentsAntimycoticsDiseaseDrug conjugation
The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
Owner:A28 THERAPEUTICS INC
Methods of treating cancer
ActiveUS20140072643A1Many symptomShorten the progressOrganic active ingredientsHeavy metal active ingredientsCarboplatinDocetaxel-PNP
The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
Owner:ABRAXIS BIOSCI LLC
Methods for treating hepatocellular carcinoma
ActiveUS20130115296A1Many symptomShorten the progressBiocideOrganic active ingredientsNanoparticleHepatocellular carcinoma
The present invention provides methods and compositions for treating hepatocellular carcinoma (HCC) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating HCC comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent, such as an agent that inhibits microtubule disassembly.
Owner:ABRAXIS BIOSCI LLC
Methods of treating bladder cancer
InactiveUS20130266659A1Delay is slowShrink tumorOrganic active ingredientsPowder deliveryNanoparticleOncology
The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise a taxane and an albumin.
Owner:ABRAXIS BIOSCI LLC
Methods for immunotherapy of cancer
InactiveUS20060286074A1Reduce or eliminate impactAvoid immune responseBiocidePeptide/protein ingredientsAntigenTumor vessel
Provided are methods of generating an immune response to an antigen specifically associated with tumor vascular endothelial cells (TVECA). The method comprises administering to an individual an expression vector encoding the TVECA. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing a TVECA and CD40 ligand. In other methods, administration of a fusion protein containing the TVECA and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. Further methods comprise the combination therapy using an expression vector encoding a secretable TVECA fusion protein and a tumor antigen vaccine.
Owner:SIDNEY KIMMEL CANCER CENT
Methods for treating hepatocellular carcinoma
InactiveUS20140079787A1Many symptomShorten the progressPowder deliveryBiocideMicrotubuleNanoparticle
Owner:ABRAXIS BIOSCI LLC
Treatment of cancer with heterocyclic inhibitors of glutaminase
InactiveUS20150004134A1Shrink tumorBiocideHeavy metal active ingredientsGlutaminaseCombinatorial chemistry
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
Owner:CALITHERA BIOSCIENCES INC
Heterocyclic glutaminase inhibitors
Owner:CALITHERA BIOSCIENCES INC
Tea catechin formulations and processes for making same
InactiveUS6428818B1Inhibit activity of specificMinimal levelBiocideHydroxy compound active ingredientsSolid tumorGreen tea
The invention described herein encompasses methods and compositions of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, a group of polyphenols found in green tea, to a mammal in need of such therapy. Compositions of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). The unique compositions of the invention contain various combinations of the catechins with reduced levels of EGCg, alone or in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses the varying modes of administration of the therapeutic compounds.
Owner:PURDUE RES FOUND INC +1
Tea catechins as cancer specific proliferation inhibitors
InactiveUS6410061B1Good treatment effectReduce adverse effectsBiocideHydroxy compound active ingredientsSolid tumorGreen tea
The invention described herein encompasses a methods and compositions of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, a group of polyphenols found in green tea, to a mammal in need of such therapy. Compositions of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). The unique compositions of the invention contain various combinations of the catechins, alone or in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses the varying modes of administration of the therapeutic compounds.
Owner:PURDUE RES FOUND INC
Method and Apparatus Including Use of Metalloporphyrins for Subsequent Optimization of Radiosurgery and Radiotherapy
InactiveUS20070043289A1Selective uptakeEfficient deliveryTelevision system detailsTelevision system scanning detailsRadiosurgeryDual delivery
Owner:ADAIR
PEI: DNA vector formulations for in vitro and in vivo gene delivery
InactiveUS6846809B2Easy constructionGood suitPowder deliveryGenetic material ingredientsGene deliveryIn vivo
The present invention relates generally to the fields of nucleic acid transfection. More particularly, it concerns novel polycation:nucleic acid compositions, methods of preparation of such compositions and methods of transfecting cells with such compositions.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
InactiveUS20080248033A1Reduce and prevent likelihoodPrevent relapseOrganic active ingredientsPeptide/protein ingredientsStaging tumorsStage tumor
Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
Owner:GENENTECH INC
Compositions and methods for immunotherapy
InactiveUS20070292418A1Good curative effectShrink tumorAntibody ingredientsCancer antigen ingredientsUrologyImmunotherapy
The invention relates to immunotherapeutic compounds, compositions that include such compounds, and methods of using the compounds, for example, to treat an individual having, at risk for, or previously treated for a cancer.
Owner:EISIA R&D MANAGEMENT CO LTD
Cancer markers and methods of use thereof
ActiveUS20160274121A1Reduce tumor sizeProlongation of survivalCompound screeningApoptosis detectionCellular biomarkersGlobulin
The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3 / SSEA-4 / GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and / or immunogenic conjugate compositions targeting the SSEA-3 / SSEA-4 / GLOBO H associated epitopes (natural and modified) which elicit antibodies and / or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and / or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.
Owner:ACAD SINIC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com